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1. Introduction
Helicobacter pylori (H. pylori) infection causes chronic infection of the gastric mucosae and is a
major risk factor for the onset of gastric cancer via a series of steps comprising gastritis, atro‐
phy, metaplasia, dysplasia and cancer [1--20]. However, in Japan and other countries with a
high rate of H. pylori infection, the presence or absence of H. pylori infection alone in diag‐
nosing gastric cancer risk is not appropriate in terms of specificity. Thus, it is necessary to
clarify the groups at high risk of gastric cancer based on the natural history of gastric cancer
development, and the evaluation of gastric cancer risk through the use of serological and
molecular biological evaluation for chronic gastritis accompanying H. pylori infection is im‐
portant [21-23]. This may contribute to both gastric cancer screening and various measures
to prevent gastric cancer, such as the formulation of follow-up plans for metachronous gas‐
tric cancer [24] after endoscopic resection [25, 26], procedures developed in Japan that have
recently been applied in the treatment of early gastric cancer.
This article describes the diagnosis of gastric cancer risk with DNA methylation as an indi‐
cator, using gastric mucosa tissue from endoscopic biopsy, which has been studied by the
authors as a molecular biological gastric cancer risk marker. Also discussed is the signifi‐
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cance of serum pepsinogen (PG) as a marker of gastric cancer risk, as recently reported by
the authors, and discusses the groups at high risk for gastric cancer based on more detailed
evaluation of H. pylori -related chronic gastritis.
2. Aberrant DNA methylation in chronic gastritis and application of
gastric cancer risk diagnosis
2.1. Concept of DNA methylation
Genetic defects in cancer include both abnormalities in genetic makeup, such as mutations
or chromosomal deletions, and epigenetic abnormalities. Deoxyribonucleic acid (DNA)
methylation is one type of epigenetic process. DNA methylation occurs physiologically, and
is observed in CpG sites where guanine (G) follows cytosine (C) in the gene sequence. CpG
sites exist with a low frequency in the genome, but there are exceptional regions where CpG
sites are clustered, called CpG islands (CGI). When a CGI is in a gene promoter region, tran‐
scription to messenger ribonucleic acid (mRNA) of downstream genes is strongly inhibited
(silencing) if that entire CGI is methylated. DNA methylation, along with mutations and
chromosomal deletions, is a major factor in the gene inactivation in many cancers [27-29].
Cancer cells show lower methylation of the entire genome and more localized high methyla‐
tion than normal cells. Low methylation of the entire genome contributes to carcinogenesis
through elicitation of genomic instability [30]. Localized high methylation means abnormal
methylation in certain CGIs among CGIs that are not normally methylated. Elicitation of
high methylation in promoter region CGIs of tumor suppressor genes causes inactivation of
that gene. This elicits cell cycle or proliferation signal abnormalities and accumulation of
mutations, and contributes to the onset and progression of cancer.
In gastric cancer and other gastrointestinal cancers, silencing of many important tumor sup‐
pressor genes has been reported. In gastric cancer in particular, cadherin 1 (CDH1), mutL
homolog 1 (MLH1) and cyclin-dependent kinase inhibitor 2A (CDKN2A) are more often in‐
activated from methylation than from mutations or chromosomal deletion [31].
2.2. Contribution of aberrant DNA methylation in carcinogenesis
Mutations in tumor suppressor genes are a genetic abnormality, and are a cause (driver) of
the onset and progression of cancer. In addition, it has been found that many secondary mu‐
tations (passengers) are also present in cancer cells with monoclonal proliferation of these
cancer cells [32]. Epigenetic abnormalities in DNA methylation play a large role in gastric
cancer, and similarly to genetic abnormalities, DNA methylation of tumor suppressor genes
can also be a driver (driver methylation) of carcinogenesis. In addition, it has been shown
that aberrant methylation in cancer cells also occurs in numerous genes other than tumor
suppressor genes (passenger methylation) [33]. Many genes with passenger methylation are
genes that originally have low levels of transcription or no transcription and are thought to
be an accompanying phenomenon to cancer development. Such aberrant DNA methylation
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in genes is seen in cancer cells, and it has also been shown to be elicited in non-cancerous
tissue as well. Numerous studies have thus been conducted on this topic.
2.3. Induction of aberrant DNA methylation in H. pylori-related chronic gastritis
In gastrointestinal organs, precancerous conditions are closely related to chronic infection
from viral or bacterial infections [34]. Chronic inflammation has also been shown to be an
important inducing factor for aberrant DNA methylation [35]. For example, greater accumu‐
lation of aberrant DNA methylation is seen in liver tissue of patients with chronic hepatitis
C, which is a background factor for hepatocellular carcinoma, than in normal liver tissue
[36]. High-level aberrant DNA methylation exists in colon mucosa tissue of patients with ul‐
cerative colitis, which is a background factor for colon cancer [37]. In the pancreas as well,
analysis of endoscopically collected pancreatic juice showed accumulation of aberrant DNA
methylation associated with the level of abnormality on pancreatic duct images [38].
When evaluating aberrant DNA methylation in non-cancerous regions, it is extremely im‐
portant to be mindful of the differences between cancerous and non-cancerous tissue [39]. In
non-cancerous tissue, which is polyclonal, quantitative evaluation that asks the question
“What is the proportion of the existence of aberrant DNA methylation in specific genes?” is
important. In other words, measuring the proportion of molecules with aberrant DNA
methylation in non-cancerous specimens (DNA methylation level) and estimating the pro‐
portion of cells in which aberrant DNA methylation has been induced will lead to accurate
evaluation of aberrant DNA methylation in non-cancerous regions. Therefore, quantitative
analysis of methylation levels is necessary to evaluate aberrant DNA methylation in the gas‐
tric mucosae, a non-cancerous region. Quantitative methylation-specific polymerase chain
reaction (MSP) is a very effective means of resolving such problems [40].
The authors conducted a detailed investigation with quantitative MSP to evaluate aberrant
DNA methylation in H. pylori -infected gastric mucosae, a background factor for gastric can‐
cer [40]. Using gastric mucosae specimens collected endoscopically from healthy individuals
positive and negative for H. pylori infection, the DNA methylation level was measured in
CpG islands in eight regions of seven genes (Lysyl Oxidase (LOX), heart and neural crest
derivatives expressed 1 (HAND1), thrombomodulin (THBD), p41ARC, CDKN2A, filamin C
(FLNc), HRAS-like suppressor (HRASLS)), in which DNA methylation is seen with high fre‐
quency in gastric cancer [41]. The level of DNA methylation was 5.4– to 303- fold higher in
the gastric mucosae of individuals positive for H. pylori infection than in those who were
negative. THBD and other passenger methylation showed particularly high DNA methyla‐
tion levels when compared with driver methylation such as in CDKN2A, which is a tumor
suppressor gene (Fig. 1). Certain characteristics are seen in genes with aberrant DNA meth‐
ylation in H. pylori-infected gastric mucosae. Low gene expression levels in gastric mucosae
are thought to be a possible predisposing factor (methylation susceptibility) in the elicitation
of DNA methylation [42]. This strongly suggests that high levels of aberrant DNA methyla‐
tion are seen in H. pylori -infected gastric mucosae and that H. pylori infection induces aber‐
rant DNA methylation. It has been shown in animal experiments that H. pylori infection
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induces aberrant DNA methylation and inflammation of gastric mucosae evoked by infec‐
tion is important in inducing aberrant DNA methylation [43].
Figure 1. Relationship between H. pylori infection, presence or absence of gastric cancer, and gastric mucosae methyl‐
ation level (citation changed from Reference 40)
Mean methylation level of cyclin-dependent kinase inhibitor 2A (CDKN2A) and thrombo‐
modulin (THBD) genes in gastric mucosae endoscopic specimens measured using the quan‐
titative methylation-specific polymerase chain reaction (MSP) method. In cases when there
is no current H. pylori infection, non-cancerous gastric mucosae of gastric cancer patients (Pt)
shows a higher methylation level than the gastric mucosae of healthy volunteers (HV). In
the case of H. pylori infection, the methylation level was high, irrespective of whether the
person had gastric cancer. High levels of aberrant DNA methylation are seen in H. pylori -
infected gastric mucosae and that H. pylori infection induces aberrant DNA methylation.
Ease of methylation differs depending on CpG islands (CGI), and the induction of methyla‐
tion is much lower in CDKN2A than in THBD. Error bars indicate standard error.
2.4. Hypomethylation of repetitive elements in H. pylori-infected gastric mucosae
Global hypomethylation during gastric carcinogenesis remains unclear, not only when but
also where in the genome it takes place. Repetitive elements such as LINE, Alu, and Satα,
which occupy some 40% of the entire genome, have abundant CpG and a physiologically
high DNA methylation state in normal cells. In cancer cells, however, all of these repetitive
elements have a low methylation state. As a result, the overall genome has low methylation
(low total amount of 5-methylcytosine), which is thought to lead to genome instability. In H.
pylori -infected gastric mucosae, it has been shown that low methylation similar to that in
cancer is already seen in repetitive elements of Alu and Satα [44]. In enlarged-fold gastritis,
for which a relationship with poorly differentiated gastric cancer has been indicated, the
DNA methylation level of LINE-1 is reported to be lower than in normal gastric mucosae or
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chronic gastritis without an enlarged fold [45]. There is a strong possibility that hypomethy‐
lation of repetitive elements is induced partially in H. pylori infected gastric mucosae. Fur‐
ther investigation will be necessary in the future with regard to the role of chronic
inflammation associated with H. pylori infection in inducing hypomethylation of repetitive
elements.
2.5. Accumulation of aberrant DNA methylation in gastric mucosae and gastric cancer
risk
The DNA methylation levels of gastric mucosae of healthy individuals and non-cancerous
gastric mucosae of gastric cancer patients were investigated with respect to the relationship
between aberrant DNA methylation and gastric cancer risk (Fig. 1). The results showed that
while the methylation levels were high and there were no significant differences between
those who were positive for H. pylori infection, methylation levels were low and inhibited in
those who were negative for current HP infection, and were 2- to 32- fold higher in the non-
cancerous gastric mucosae of gastric cancer patients than in the gastric mucosae of healthy
indivudals [40]. In other groups, DNA methylation levels were also investigated in the non-
cancerous gastric mucosae of multiple gastric cancer patients, non-cancerous gastric muco‐
sae of single gastric cancer patients, and gastric mucosae of healthy individuals, and it was
found that in individuals negative for current H. pylori infection the DNA methylation level
of FLNc, HAND1 and THBD in particular was correlated with gastric cancer risk [46]. These
are known as passenger methylations, but DNA methylation levels were high as a whole,
and so quantitative measurement was simple and application as a cancer risk marker is
thought to be possible. Mean DNA methylation of tumor suppressor genes CDKN2A and
MLH1 was very low, and it would be difficult to use these as cancer risk markers. However,
among microRNA genes that function as tumor suppressor genes, some have high DNA
methylation levels, as well as correlations with gastric cancer risk [47].
As shown above, passenger genes and microRNA genes are methylated in many cells in
gastric mucosae by H. pylori infection, and tumor suppressor genes are thought to be methy‐
lated in a proportionately smaller number of cells. A high cancer risk state (epigenetic field
for cancerization) is thought to be formed by this accumulation [48]. In gastric cancers, an
epigenetic field for cancerization is likely to be present and can be detected using appropri‐
ate marker genes.
2.6. Progress of gastric mucosae DNA methylation level and gastric cancer risk diagnosis
H. pylori infection potently induces aberrant DNA methylation in gastric mucosae, and its
accumulation is associated with gastric cancer risk. To clarify the temporal profiles of aber‐
rant DNA methylation in gastric mucosae, we analyzed time trends of FLNc and THBD
methylation levels in gastric mucosae before, and six weeks and 1 year after H. pylori eradi‐
cation by Quantitative MSP. With respect to the relationship between aberrant DNA methyl‐
ation in gastric mucosae and H. pylori eradication therapy, the authors investigated the trend
in DNA methylation before and after H. pylori eradication therapy. After bacterial elimina‐
tion, the DNA methylation levels decreased after six weeks and one year together with the
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improvement in chronic inflammation associated with H. pylori infection, and a certain level
of DNA methylation remained [49].
A model such as in Fig. 2 is assumed if the DNA methylation that disappeared with H. pylori
eradication is temporarily methylated and the DNA methylation that remained after bacteri‐
al elimination is permanently methylated. In other words, in cases of existing H. pylori infec‐
tion, DNA methylation is strongly induced in cells of the entire gland, but if chronic
inflammation resolves with H. pylori eradication therapy or spontaneous H. pylori elimina‐
tion from the progression of gastric mucosal atrophy, the elicitation of new DNA methyla‐
tion is decreased. Perhaps the DNA methylation that occurred in differentiated ductal
epithelial cells disappears with cell turnover, and the aberrant DNA methylation that occurs
in ductal stem cells or progenitor cells remains, even with resolution of chronic inflamma‐
tion, reflecting the gastric cancer risk. It is possible that individuals with low levels of this
permanent methylation also have a low risk of gastric cancer, and conversely, that those
with high levels also have a high risk of gastric cancer. A prospective clinical trial is current‐
ly underway to test this.
Figure 2. Model of the course of DNA methylation in H. pylori-infected gastric mucosae
DNA methylation is assumed to include temporary methylation, which is induced only dur‐
ing the time H. pylori infection is present, and permanent methylation that persists even af‐
ter H. pylori infection has been eliminated with eradication therapy. Time point 1: Without
H. pylori infection, the methylation is initially. Time points: 2–4, H. pylori infection induces
both permanent and temporary components of methylation, and the total methylation level
fluctuates due to fluctuation of the temporary component. Time points 5–6: after H. pylori
infection discontinues, the temporary component disappears, and the increase in the perma‐
nent component stops. Permanent methylation very likely reflects gastric cancer risk.
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3. Identification of gastric cancer risk group by serum PG test
3.1. Evaluation of H. pylori-related chronic gastritis by PG test
H. pylori -related chronic gastritis normally spreads from the gastric antrum to the gastric
corpus [50, 51], and the progression of chronic atrophic gastritis (CAG) increases the risk for
cancer [52-56]. An accurate and reliable evaluation of the extent of CAG is considered to be
important for identifying high-risk individuals for cancer; however, it is difficult to accurate‐
ly diagnose the extent of CAG based on a few biopsy samples, as CAG and intestinal meta‐
plasia represent a multifocal process. Furthermore, histological diagnosis of gastric atrophy
depends on subjective judgment without a gold standard [57, 58]. A more convenient and
economical test for CAG progression, free of discomfort or risk and based on objective pa‐
rameters, is necessary.
PG is an inactive precursor of the digestive enzyme pepsin produced exclusively in the
stomach. Immunologically, there are two isoenzymes [59]. PG I is produced by chief cells
and mucous neck cells of the fundic gland region. PG II, in addition to chief cells and mu‐
cous neck cells, is produced in the cardiac glands, pyloric glands and Brunner’s glands, with
producing cells located over a wide range from the stomach through the duodenum. The
majority of PG produced (about 99%) is secreted in the gastric lumen and acts as a digestive
enzyme, but a very small amount of PG (about 1%) is also located in the blood and can be
measured and evaluated as serum PG. There is general agreement that serum PG levels re‐
flect the morphological and functional status of the stomach mucosa [60, 61].
When the gland margin elevates with the progression of gastric mucosal atrophy diagnosed
with chromoendoscopy using Congo red, a high correlation is seen in the incremental de‐
crease in serum PG I levels and PG I/II ratio [62]. Thus, by measuring serum PG I levels and
PG I/II ratio, it is possible to objectively evaluate the progress of CAG, which is the bed
where gastric cancer develops [63]. In addition, elevated serum PG I and PG II levels and
decreased PG I/II ratio are observed at the time of H. pylori infection, and have been shown
to improve after eradication therapy [64], making them useful as inflammation markers of
gastric mucosae.
Various criteria are used in the serum PG test. As criteria for the purpose of gastric cancer
screening, a combination of PG I ≤70 ng/ml and PG I/II of ≤3.0, the reference value by Miki et
al., has generally been adopted (PG index 1+) [63, 65]. When levels below the reference value
are observed, the PG test is judged to be positive. In addition to this reference value, criteria
such as PG I ≤50 ng/ml and PG I/II ratio ≤3.0 (PG index 2+), or PG I ≤30 ng/ml and PG I/II
ratio ≤2.0 (PG index 3+), are the main criteria used to identify more highly advanced CAG.
Since 1992, when PG assay kits became commercially available, a number of screening serv‐
ices provided by workplace or community health services adopted this serum test as a filter
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test [21, 66-71]. However, the long-term prognosis of subjects with extensive CAG identified
by PG filter test is not fully known.
3.2. Accuracy of detecting gastric cancer using the serum PG test
Using a cohort of healthy middle-aged males, the authors conducted a 10-year follow-up
survey of gastric cancer development [72-74]. Based on the results, the accuracy of each cri‐
terion for the serum PG test for gastric cancer with onset in the observation period was in‐
vestigated [73]. With the best reference value (PG index 1+), sensitivity was 58.7%,
specificity was 73.4%, and the positive predictive value was 2.6%. The low value for the
overall sensitivity was conspicuous. Compared with a report from a meta-analysis of the ac‐
curacy of the PG test [75], these results were obviously poorer, with the low value for sensi‐
tivity in particular standing out.
One reason for this low sensitivity is thought to be that the patients in past reports of the
above-mentioned meta-analysis were groups in which analysis had been performed soon af‐
ter the start of the PG test and conventional stomach examinations by barium stomach x-ray.
In other words, the subjects were groups with gastric cancer prevalence that did not fit well
with conventional methods. The low sensitivity in the authors’ investigation was thought to
be because patients who developed gastric cancer soon after the start of the PG test were ex‐
cluded, and the observations were of individuals who developed cancer over a longer peri‐
od of 10 years. From the results of this study, even when performed with the PG test criteria
having the best sensitivity, barium stomach x-ray test or some other type of stomach exami‐
nation was thought to be essential, even for PG test-negative patients, to avoid overlooking
gastric cancer, as about 40% of developed gastric cancer was excluded from the subjects of
the accuracy test.
3.3. Gastric cancer risk in serum PG test-positive group
As one part of an investigation of the natural history of gastric cancer development, the
authors investigated the gastric cancer risk in cohorts identified using each of the serum
PG tests [73]. When the subjects were healthy middle-aged males, the annual gastric can‐
cer incidence from the atrophy-negative group was 0.07%, when compared with 0.28% in
the PG index 1+ group, 0.32% in the PG index 2+ group, and 0.42% in the PG index 3+
group. The gastric cancer incidence rose incrementally and significantly with the progres‐
sion of  CAG (Fig.  3).  The above results  thus  show that  the  PG test-positive  group is  a
high risk group for gastric  cancer,  and even if  the development of  gastric  cancer is  not
seen at  this time, the possibility that they will  be affected with gastric cancer in the fu‐
ture is  high,  and therefore these subjects  should continue to undergo detailed examina‐
tions and be carefully observed. Thus, the results show again that the PG test is useful as
a marker for high risk of gastric cancer.
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Figure 3. Kaplan-Meier analysis of gastric cancer development in subjects classified using the criteria of the serum PG
test
The annual incidence of gastric cancer in cohorts identified using each serum PG test cut-off
value (PG I ≤70 ng/ml and PG I/II of ≤3.0 (PG index 1+), PG I ≤50 ng/ml and PG I/II ratio ≤3.0
(PG index 2+), or PG I ≤30 ng/ml and PG I/II ratio ≤2.0 (PG index 3+)) in healthy middle-aged
males is shown. Gastric cancer incidence increases in a stepwise fashion and significantly
with the progression of chronic atrophic gastritis.
3.4. Identification of high risk for gastric cancer based on staging of H. pylori-related
chronic gastritis
The relationship between the risk of developing gastric cancer and H. pylori-related chronic
gastritis staging was also investigated in these same groups [72, 74]. In diagnosing H. pylori in‐
fection, anti- H. pylori antibody titer that can be easily performed with blood tests, similarly to
serum PG levels, was used. H. pylori -related chronic gastritis stage, including the course from
establishment of H. pylori infection to establishment of atrophic gastritis, was classified as fol‐
lows based on a combination of both blood tests. The natural history of H. pylori -related chron‐
ic gastritis from the establishment of H. pylori infection can be expressed as a progression of A
→ B → C → D in each group. Thus, it is classified into four stages: Group A [H. pylori (-) &
PG(-)], Group B [H. pylori (+) & PG(-)], Group C [H. pylori (+) & PG(+)] and Group D [H. pylori (-)
& PG(+)]. Group A comprised H. pylori non-infected healthy men. Group B showed establish‐
ed H. pylori infection, but without CAG. Group C had CAG, and Group D had severe intesti‐
nal  metaplasia  due  to  progression  of  CAG.  However,  H.  pylori  in  Group  D  had  been
spontaneously eliminated, representing so-called metaplastic gastritis.
The results of a 10-year follow-up survey showed that the annual gastric cancer incidence in
each group with this staging was 0% in Group A (no occurrence of gastric cancer in 10 years
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in this group), 0.11% in Group B (1 in 1,000 individuals developed gastric cancer each year),
0.24% in Group C (1 in 400 individuals developed gastric cancer each year) and 1.31% in
Group D (1 in about 80 individuals developed gastric cancer each year). Similar results were
observed in a study by Watabe et al.[76]. The above shows that gastric cancer incidence rises
incrementally together with the stage progression of H. pylori-related chronic gastritis (Fig.
4). In the 10-year follow-up survey, all of those who developed gastric cancer were positive
for H. pylori infection. This shows that nearly all cases of gastric cancer in Japan derive from
H. pylori-related chronic gastritis. Based on this fact, it is theoretically possible to identify
both high- and low-risk groups (Group A). Using blood test results in this way, the evalua‐
tion of the gastric cancer risk in individuals is possible and expected to be useful in group‐
ing individuals for appropriate gastric cancer screening.
Figure 4. Gastric cancer risk based on H. pylori-related chronic gastritis stage classification
H. pylori-related chronic gastritis stage classified based on a combination of both Serum PG
test and H. pylori antibody is shown. The gastric cancer incidence in healthy middle-aged
males increases incrementally and significantly from Group A to Group D in accordance
with stage progression.
3.5. Gastric cancer risk in serum PG test-negative group
Even though the serum PG test was shown to be a very useful test as a marker of gastric
cancer risk, gastric cancer (particularly diffuse type gastric cancer) was seen in the PG test-
negative group. In the authors’ investigation, about 40% of gastric cancers were found to be
PG test-negative gastric cancers, even using the PG test criteria (PG index 1+) that are
thought to have the best balance for test accuracy. This needs to be kept fully in mind when
diagnosing gastric cancer risk with the serum PG test. Even in the PG test-negative group,
there is thought to be one group in which gastric cancer occurs with a high frequency in
Group B of the H. pylori -related chronic gastritis staging. Serum PG levels are specific risk
markers of gastric cancer development. The risk of developing cancer has been confirmed to
increase incrementally with lower PG I levels and I/II ratio in particular [74].
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Reviewing the PG-negative group based on this result, it was found to consist of three
groups with different risks. Specifically, the PG test-negative group was further divided into
three groups: Group α (serum PG I ≤70 ng/ml and PG I/II >3); Group β (serum PG I >70
ng/ml and PG I/II >3); and Group γ (serum PG I >70 ng/ml and PG I/II ≤3). The gastric cancer
incidence in Group γ, which showed high serum PG II levels and is thought to have strong
inflammation in the gastric mucosae, reached 0.2%, meaning this was a new high-risk
group, in which mainly undifferentiated gastric cancer occurs (Fig. 5) [73]. Although the
percentage in Group γ was not particularly high in the PG test-negative group, it is a sub‐
group that should be kept fully in mind. Furthermore, similarly to serum PG II levels, the
group with high anti- H. pylori antibody titer, which is thought to be an indicator reflecting
the level of inflammation, was shown to have a higher incidence of gastric cancer than the
low group [74]. In addition, it was shown recently that in Group γ in particular, there are
many cases of undifferentiated gastric cancer in individuals with high H. pylori antibody tit‐
er and endoscopic rugal hyperplastic gastritis[77]. The possibility of gastric cancer inhibition
effects from H. pylori eradication therapy in such groups has also been demonstrated [78].
Figure 5. Group determination based on serum PG test and gastric cancer incidence
Schematic presentation of the atrophy-positive criterion and pepsinogen index, which are
widely used for the PG filter test in Japan. PG index is used to detect subjects with severe
gastric atrophy by subdividing the atrophy-positive criterion identified by PG I of ≤70
ng/mL and PG I/II ratio of ≤3.0 into three groups (PG index 1+ to 3+). Gastric cancer inci‐
dence increases in a stepwise fashion and significantly with the progression of chronic atro‐
phic gastritis. In addition, the figure illustrates three subgroups, groups α, β, and γ, in the
atrophy-negative criterion. The gastric cancer incidence in Group γ reached 0.2%, meaning
this was a new high-risk group, in which mainly undifferentiated gastric cancer occurs.
3.6. Points to bear in mind in diagnosing gastric cancer risk from serum PG test
In the PG test-negative group, the development of cancer in Group A in the H. pylori-related
chronic gastritis staging (PG test-negative and H. pylori judgment-negative) was not seen in
a single case in the 10-year follow-up survey by the authors, but there are points to be mind‐
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ful of in terms of the definitive diagnosis of a patient being in Group A. First is that when H.
pylori antibody titer measurement kits have low sensitivity, the antibody titer may be nega‐
tive despite existing HP infection. Second is the need for attention in patients who have un‐
dergone H. pylori eradication (they are negative for H. pylori but the risk of developing
gastric cancer is not zero). Third is that, with regard to judging risk from serum PG levels, it
cannot be applied in kidney failure patients or patients taking proton pump inhibitors (PPI)
following gastrectomy. In addition, the authors have reported that individuals with PG I/II
ratio ≤3.0, serum PG I ≤30 ng/ml, or serum PG II >30 ng/ml have a significantly higher risk of
gastric cancer [74]. Thus, when the PG I/II ratio is ≤3.0 or serum PG I is ≤30 ng/ml, even in
Group A, endoscopic examination should be performed and CAG should be evaluated.
4. Conclusion
Diagnosis of gastric cancer risk using the accumulation of aberrant DNA methylation in the
gastric mucosae in endoscopic biopsy tissue and identification of high-risk gastric cancer
groups based on serum PG test is discussed (Fig. 6). More effective measures for the preven‐
tion of gastric cancer may be possible with specific predictions of gastric cancer risk in indi‐
viduals based on the natural history of H. pylori -related chronic gastritis, and future
research results are anticipated.
Figure 6. Schematic presentation of gastric cancer risk diagnosis based on H. pylori -related chronic gastritis. This arti‐
cle indicated that DNA methylation level of certain genes was associated with H. pylori infection and involved in the
formation of epigenetic field for cancerization. The serum PG and/or H. pylori antibody levels provide an index of gas‐
tric cancer development, and that based on these markers the risk for gastric cancer can be objectively determined in
each individual with H. pylori related chronic gastritis.
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